Shield Therapeutics US market offers a significant opportunity

Shield Therapeutics plc (LON:STX) is the topic of conversation when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the company’s underperformance, explains how he thinks the shares could recover, how returns will be better if Shield sells Accrufer itself, why he thinks shares are still falling and sums up his thoughts on the company.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals.

You might also enjoy reading  Shield Therapeutics: Looking to accelerate positive signals in the US
Find more news, interviews, share price & company profile here for:
Hardman & Co

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Hardman & Co
Shield Therapeutics US market offers a significant opportunity

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions